XML 99 R16.htm IDEA: XBRL DOCUMENT v3.19.3
Intangible Assets
 9 Months Ended
Sep. 30, 2019
Intangible Assets, Net (Excluding Goodwill) [Abstract]  
Intangible Assets
INTANGIBLE ASSETS
The following table summarizes our intangible assets, net (in millions):
 
 
September 30, 2019
 
December 31, 2018
 
 
Gross 
Carrying
Amount
 
Accumulated
Amortization
 
Foreign Currency Translation Adjustment
 
Net Carrying Amount
 
Gross 
Carrying
Amount
 
Accumulated
Amortization
 
Foreign Currency Translation Adjustment
 
Net Carrying Amount
Finite-lived assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intangible asset - sofosbuvir
 
$
10,720

 
$
(4,078
)
 
$
—

 
$
6,642

 
$
10,720

 
$
(3,554
)
 
$
—

 
$
7,166

Intangible asset - axicabtagene ciloleucel (DLBCL)
 
6,200

 
(675
)
 
—

 
5,525

 
6,200

 
(416
)
 
—

 
5,784

Intangible asset - Ranexa
 
688

 
(688
)
 
—

 
—

 
688

 
(678
)
 
—

 
10

Other
 
1,098

 
(434
)
 
(7
)
 
657

 
1,096

 
(359
)
 
(3
)
 
734

Total finite-lived assets
 
18,706

 
(5,875
)
 
(7
)
 
12,824

 
18,704

 
(5,007
)
 
(3
)
 
13,694

Indefinite-lived assets - in process research & development
 
2,047

 
—

 
(7
)
 
2,040

 
2,047

 
—

 
(3
)
 
2,044

Total intangible assets
 
$
20,753

 
$
(5,875
)
 
$
(14
)
 
$
14,864

 
$
20,751

 
$
(5,007
)
 
$
(6
)
 
$
15,738


Aggregate amortization expense related to finite-lived intangible assets was $281 million and $868 million for the three and nine months ended September 30, 2019, respectively, and $301 million and $902 million for the three and nine months ended September 30, 2018, respectively, and was primarily included in Cost of goods sold on our Condensed Consolidated Statements of Operations.
The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of September 30, 2019 (in millions):
Fiscal Year
 
Amount
2019 (remaining three months)
 
$
281

2020
 
1,125

2021
 
1,124

2022
 
1,124

2023
 
1,124

Thereafter
 
8,046

Total
 
$
12,824